Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 12
Submit an article Journal homepage
4,116
Views
8
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

Margaret E. GerbasiPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Daniel StellatoPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Sameer R. GhateNovartis Pharmaceuticals Corp, East Hanover, NJ, USA;
,
Briana NdifeNovartis Pharmaceuticals Corp, East Hanover, NJ, USA;
,
Aaron MoynahanPolicy Analysis Inc. (PAI), Brookline, MA, USA;
,
Dinesh MishraNovartis Pharmaceuticals Corp, Hyderabad, India
,
Praveen GundaNovartis Pharmaceuticals Corp, Hyderabad, India
,
Roy KoruthNovartis Pharmaceuticals Corp, Hyderabad, India
&
Thomas E. DeleaPolicy Analysis Inc. (PAI), Brookline, MA, USA; Correspondence[email protected]
 show all
Pages 1243-1252 | Received 20 Mar 2019, Accepted 20 Jun 2019, Published online: 04 Aug 2019

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.